Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 17.08
+0.10 (0.59%)
Sep 4, 2026, 5:00 PM CET
Ryvu Therapeutics Ratios and Metrics
Market cap in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 395 | 627 | 890 | 1,329 | 1,139 | 1,120 | |
Market Cap Growth | -37.44% | -29.61% | -33.04% | 16.75% | 1.70% | 23.98% |
Enterprise Value | 408 | 585 | 755 | 1,082 | 1,098 | 1,035 |
Last Close Price | 17.08 | 27.10 | 38.50 | 57.50 | 49.25 | 61.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 163.70 | 163.70 | 163.70 | 163.70 | 163.70 |
PS Ratio | 4.47 | 7.14 | 8.73 | 19.76 | 16.64 | 31.62 |
PB Ratio | 9.56 | 11.64 | 5.85 | 5.12 | 3.32 | 6.94 |
P/TBV Ratio | 11.28 | 13.11 | 6.17 | 5.25 | 3.36 | 7.08 |
P/FCF Ratio | - | - | - | - | 75.58 | - |
P/OCF Ratio | - | - | - | - | 53.41 | - |
PEG Ratio | - | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.61 | 6.67 | 7.41 | 16.08 | 16.05 | 29.21 |
EV/FCF Ratio | - | - | - | - | 72.90 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 2.32 | 1.78 | 0.67 | 0.04 | 0.04 | 0.08 |
Debt / FCF Ratio | - | - | - | - | 0.84 | - |
Net Debt / Equity Ratio | 0.31 | -0.22 | -0.81 | -0.86 | -0.26 | -0.46 |
Net Debt / EBITDA Ratio | -0.18 | 0.13 | 1.11 | 2.56 | 1.54 | 1.11 |
Net Debt / FCF Ratio | -0.13 | 0.10 | 0.92 | 2.40 | -5.96 | 1.06 |
Asset Turnover | 0.34 | 0.29 | 0.26 | 0.15 | 0.19 | 0.14 |
Inventory Turnover | 11.96 | 11.63 | 11.77 | 9.06 | 9.37 | 7.56 |
Quick Ratio | 2.04 | 2.08 | 2.42 | 3.82 | 8.09 | 2.76 |
Current Ratio | 2.26 | 2.26 | 2.52 | 3.99 | 8.21 | 2.88 |
Return on Equity (ROE) | -110.11% | -98.22% | -54.11% | -30.55% | -33.20% | -41.08% |
Return on Assets (ROA) | -19.70% | -20.14% | -19.50% | -13.86% | -12.34% | -18.80% |
Return on Invested Capital (ROIC) | -170.00% | -275.62% | -380.19% | -67.32% | -40.89% | -101.00% |
Return on Capital Employed (ROCE) | -54.90% | -59.70% | -45.00% | -29.20% | -16.20% | -41.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -22.44% | -16.16% | -12.52% | -6.93% | -7.36% | -7.06% |
FCF Yield | -25.37% | -19.40% | -15.21% | -7.00% | 1.32% | -6.33% |
Buyback Yield / Dilution | 4.90% | - | -0.97% | -24.75% | - | -9.48% |